CY1107954T1 - Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd - Google Patents

Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd

Info

Publication number
CY1107954T1
CY1107954T1 CY20081100527T CY081100527T CY1107954T1 CY 1107954 T1 CY1107954 T1 CY 1107954T1 CY 20081100527 T CY20081100527 T CY 20081100527T CY 081100527 T CY081100527 T CY 081100527T CY 1107954 T1 CY1107954 T1 CY 1107954T1
Authority
CY
Cyprus
Prior art keywords
mglur5
competitors
treatment
gerd treatment
antagonists
Prior art date
Application number
CY20081100527T
Other languages
Greek (el)
English (en)
Inventor
Anders Lehmann
Jan Mattsson
Thomas M Stormann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107954(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1107954T1 publication Critical patent/CY1107954T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20081100527T 2002-06-20 2008-05-21 Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd CY1107954T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use
EP03731333A EP1513525B1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd

Publications (1)

Publication Number Publication Date
CY1107954T1 true CY1107954T1 (el) 2013-09-04

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100527T CY1107954T1 (el) 2002-06-20 2008-05-21 Χρηση mglur5 ανταγωνιστων για τηn θεραπεια gerd

Country Status (24)

Country Link
EP (1) EP1513525B1 (enExample)
JP (2) JP4683920B2 (enExample)
CN (1) CN100430056C (enExample)
AT (1) ATE395059T1 (enExample)
AU (1) AU2003241585B2 (enExample)
BR (1) BR0311759A (enExample)
CA (1) CA2489730C (enExample)
CY (1) CY1107954T1 (enExample)
DE (1) DE60320990D1 (enExample)
DK (1) DK1513525T3 (enExample)
ES (1) ES2304510T3 (enExample)
IL (1) IL165138A0 (enExample)
IS (1) IS7654A (enExample)
MX (1) MXPA04012659A (enExample)
NO (1) NO20050154L (enExample)
NZ (1) NZ536559A (enExample)
PL (1) PL372186A1 (enExample)
PT (1) PT1513525E (enExample)
RU (1) RU2324484C2 (enExample)
SE (1) SE0201943D0 (enExample)
SI (1) SI1513525T1 (enExample)
UA (1) UA81627C2 (enExample)
WO (1) WO2004000316A1 (enExample)
ZA (1) ZA200409908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AU2005214376A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
SG149900A1 (en) * 2004-02-18 2009-02-27 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
MX2008012413A (es) * 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
WO2010000763A2 (en) 2008-06-30 2010-01-07 Novartis Ag Combination products
EP2456438A2 (en) 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
CA2800970A1 (en) 2010-06-24 2011-12-29 Novartis Ag Use of 1h-quinazoline-2,4-diones
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
CA2846503A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy
JP6137336B2 (ja) 2013-01-15 2017-05-31 ノバルティス アーゲー ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用
MX379289B (es) 2013-01-15 2025-03-10 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
EP4007575B1 (en) * 2019-11-05 2023-09-27 Claes THULIN 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of stress

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
JP2002515448A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 食道逆流病の処置法
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
ATE307129T1 (de) * 1999-08-19 2005-11-15 Nps Pharma Inc Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
CN1703403A (zh) * 2000-10-02 2005-11-30 詹森药业有限公司 趋代谢的谷氨酸盐受体拮抗剂

Also Published As

Publication number Publication date
DK1513525T3 (da) 2008-08-11
MXPA04012659A (es) 2006-05-25
ATE395059T1 (de) 2008-05-15
RU2324484C2 (ru) 2008-05-20
IS7654A (is) 2005-01-19
SE0201943D0 (sv) 2002-06-20
BR0311759A (pt) 2005-03-08
RU2005101411A (ru) 2005-07-10
AU2003241585A1 (en) 2004-01-06
IL165138A0 (en) 2005-12-18
PT1513525E (pt) 2008-06-24
HK1075833A1 (en) 2005-12-30
PL372186A1 (en) 2005-07-11
NO20050154L (no) 2005-01-11
AU2003241585B2 (en) 2009-06-25
ZA200409908B (en) 2006-08-30
UA81627C2 (ru) 2008-01-25
JP2011068669A (ja) 2011-04-07
EP1513525A1 (en) 2005-03-16
CA2489730C (en) 2011-11-22
NZ536559A (en) 2007-08-31
CA2489730A1 (en) 2003-12-31
DE60320990D1 (de) 2008-06-26
EP1513525B1 (en) 2008-05-14
CN100430056C (zh) 2008-11-05
SI1513525T1 (sl) 2008-08-31
WO2004000316A1 (en) 2003-12-31
JP2006507225A (ja) 2006-03-02
JP4683920B2 (ja) 2011-05-18
CN1662235A (zh) 2005-08-31
ES2304510T3 (es) 2008-10-16

Similar Documents

Publication Publication Date Title
DK1513525T3 (da) Anvendelse af MGLUR5-antagonister til behandling af GERD
DE60205481D1 (de) Furan and thiophen derivate die menschliche peroxisome proliferator aktivierte receptoren aktivieren
ATE345128T1 (de) Modulatoren der peroxisom-proliferator- aktivierten rezeptoren (ppar)
NO20020823L (no) Heteropolysykliske forbindelser og deres anvendelse som metabotropiske glutamatreseptorantagonister
WO2005077368A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
DK1444233T3 (da) A2B-adenosinreceptorantagonister
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
EP1773774A4 (en) HETEROCYCLIC ACETOPHENONE AMPLIFIERS OF METABOTROPIC GLUTAMATE RECEPTORS
ITMI20021620A1 (it) Composto ad ativita' antitumorale
CY1112135T1 (el) Ανταγωνιστες υποδοχεα il-8
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
BR0108867A (pt) Antagonistas de receptor il-8
WO2003043619A8 (en) New use for the treatment of gastroesophageal reflux disease
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
ATE358128T1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
PE20020052A1 (es) Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato
BRPI0517024A (pt) conjugados com atividade antiinflamatória
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
BR0000486A (pt) Antagonistas do neuropeptìdeo y
SE0303492D0 (sv) New use VII
SE0303491D0 (sv) New use VI
ATE285759T1 (de) Neuropeptid y antagonisten